Newsroom | 42914 results

PARIGI--(BUSINESS WIRE)--Candela, leader globale nelle tecnologie estetiche basate sull'energia, ha annunciato oggi il lancio europeo del sistema Glacē™, una piattaforma di trattamento per il viso che segna un nuovo audace capitolo per l'azienda e il futuro della medicina estetica. Oltre al lancio del sistema Glacē, Candela esporrà a IMCAS 2026 anche il suo sistema Matrix per il rinnovamento cutaneo e la sua iconica piattaforma per il trattamento vascolare Vbeam® Pro. Entrambe le piattaforme Ma...

PARIS--(BUSINESS WIRE)--Candela, ein weltweit führender Anbieter von energiebasierten ästhetischen Technologien, gab heute die europäische Markteinführung des Glacē™-Systems bekannt, einer Plattform für Gesichtsbehandlungen, die ein neues Kapitel für das Unternehmen und die Zukunft der ästhetischen Medizin einläutet. Neben der Einführung des Glacē-Systems wird Candela auf der IMCAS 2026 auch sein Matrix-System für die radiofrequenzbasierte Hauterneuerung und seine legendäre Vbeam®-Pro-Plattform...

PARÍS--(BUSINESS WIRE)--Candela, líder internacional en tecnologías estéticas basadas en energía, ha anunciado hoy el lanzamiento en Europa de Glacē™ System, una plataforma de tratamientos faciales que supone un nuevo y ambicioso capítulo para la empresa y el futuro de la medicina estética. Además del lanzamiento de Glacē System, Candela también presentará en IMCAS 2026 su sistema Matrix para la renovación cutánea mediante radiofrecuencia y su emblemática plataforma de tratamiento vascular Vbea...

PARIS--(BUSINESS WIRE)--Candela, leader mondial des technologies esthétiques basées sur l’énergie, a annoncé aujourd’hui le lancement européen du système Glacē™, une plateforme de traitement facial qui marque un nouveau chapitre audacieux pour l’entreprise et l’avenir de la médecine esthétique. Outre le lancement du système Glacē, Candela présentera également son système Matrix pour le renouvellement cutané par radiofréquence et sa plateforme de traitement vasculaire emblématique Vbeam® Pro à l...

PARIJS--(BUSINESS WIRE)--Candela, een wereldleider gespecialiseerd in estheticatechnologieën gebaseerd op energie, kondigde vandaag de Europese lancering aan van het Glacē™-systeem, een platform voor gezichtsbehandeling dat een gedurfd nieuw hoofdstuk voor het bedrijf en de toekomst van esthetische geneeskunde inluidt. Naast de lancering van het Glacē-systeem, zal Candela tijdens IMCAS 2026 ook haar Matrix-systeem voorstellen voor huidvernieuwing gebaseerd op radiofrequentie en haar emblematisc...

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced today that it has entered into a definitive securities purchase agreement for the purchase and sale of an aggregate of 2,522,727 shares of its common stock in a private placement at a price of $4.40 per share. The offering is expecte...

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today that it has closed the transaction to sell its retail and distribution businesses in Norway to NorgesGruppen, a privately owned retail group. McKesson announced on August 4, 2025, that it planned to divest Norway, included within the Other segment. The transaction represents the final step in McKesson’s commitment to fully exit its European operations. This transaction will enable McKesson to focus strategy and cap...

PARIS--(BUSINESS WIRE)--Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are...

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, announces the discharge from judicial reorganisation proceedings and ratification of the recovery plan by the Commercial Court of Lyon. This decision closes the observation pe...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) has unveiled findings from a global survey of peri- and post-menopausal women from nine countries exploring the impact of menopause on the skin at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. The survey found that over 50% of women learned about the effects of menopause on the skin by going through it themselves, with most finding out about it in their 40s.2 Howeve...